Panacea Venture — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investors3B Future Health FundCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalSeventure Partners
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investorsARCH Venture Partners5AM Ventures8VCAtlas VentureTaiho Ventures, LLCTakeda Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.








